Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial

NCT03044197 is registered in ClinicalTrials.gov with The University of Texas Medical Branch, Galveston as lead sponsor.

NCT NCT03044197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03044197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial
Lead sponsor
The University of Texas Medical Branch, Galveston
Phase
Not applicable
Overall status
Completed
Start date
July 25, 2017
Completion date
April 12, 2018
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinically significant prostate cancer, fusion biopsy, magnetic resonance imaging, prostate cancer, target lesion, transperineal